Traded Mar 2 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Feb 2, 2026 · Filed Feb 3, 2026
Alkermes's R&D, Chief Medical Officer sold $134K of Alkermes shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$134,160
Shares × reported transaction price
21 days after results of Jan 12, 2026, 23 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.7% | +0.4% | +0.3% |
| 30 days | −17.8% | −1.2% | −16.6% |
| 90 days | −0.9% | +4.1% | −5.0% |
| 180 days | +43.7% | +9.9% | +33.8% |
Past results only. Not a forecast.
Traded Mar 2 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Mar 2 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Mar 2 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.